Article
San Francisco-Clinical trials have begun evaluating the Light-Adjustable Lens (LAL, Calhoun Vision), a unique silicone-based, pseudophakic IOL that would allow for non-invasive, postoperative correction of refractive and wavefront errors, said Daniel M. Schwartz, MD.
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial